Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis

Inclusion Criteria: * Male or female with mild to severe atopic dermatitis, 12 years of age or older, that agree to participate and provide written consent (parent permission and assent if applicable). * Have an Investigator Global Assessment of mild to severe atopic dermatitis (IGA rating of 2 through 4 in the Investigator Global Assessment). * Visual Analog Scale of Itch score at Baseline must be greater than or equal to 50 on a 100-point scale. * Percentage of overall body surface area of involvement (BSA) must be ≥2%. * Women of childbearing potential will be allowed to participate in the study, and will be required to use at least one form of birth control. Exclusion Criteria: * Use within four weeks from Baseline any systemic anti-inflammatory medication, which may influence study outcome, such as systemic corticosteroids. * Application or use within two weeks of Baseline topical corticosteroid medications or topical anti-inflammatory medication, which may influence study outcome. * Presence of a concurrent medical condition, which is determined by the investigator to potentially interfere with study outcomes or patient assessments. * Introduction of any other prescription medication, topical or systemic, for atopic dermatitis while participating in the study. * Use of anti-histamines while participating in the study will not be permitted unless the subject meets criteria for anti-histamine use on the VAS scale. Additionally, the subject must remain on a stable dose of anti-histamine throughout the study period. If a patient meets such criteria for anti-histamine use, this will be noted in the subject's chart. * Amount of disease involvement that would require \>60 gm of cream in a 1 week period. * Subjects with known allergy or sensitivity to topical Vanos® cream or components. * Pregnant women * Women who are breastfeeding